[Form 4] Staar Surgical Co Insider Trading Activity

Rhea-AI Filing Summary

Jiang Wei, a director of Staar Surgical Co (STAA), had 20,967 restricted stock units (RSUs) vest on August 12, 2025. These RSUs were part of a grant made May 12, 2025 and each RSU converts into one share upon vesting. The award vests in three equal tranches of 20,967 shares on August 12, 2025, November 12, 2025 and January 12, 2026, for a total grant of 62,901 RSUs. The Form 4 shows post-transaction beneficial ownership figures and notes the RSUs relate to a consulting agreement under which Mr. Jiang serves as special strategic advisor for the companys Asia Pacific business through the end of fiscal 2025.

Insights

Financial Analyst

RSU vesting increases insider shareholdings but is routine and not likely materially market-moving.

The filing records the vesting of 20,967 RSUs on 08/12/2025 from a May 12, 2025 grant that vests in three equal tranches totaling 62,901 RSUs. Each RSU converts to one share at vesting. The Form 4 lists post-transaction positions, including direct common stock and derivative holdings. For investors, this is a compensation-related issuance rather than a cash transaction or sale; its primary effects are on insider alignment and incremental share issuance.

Corporate Governance Expert

Disclosure aligns with Section 16 reporting; the RSUs are tied to a disclosed consulting engagement for APAC strategy.

The Form 4 discloses that the RSUs were granted May 12, 2025 and that one-third vested on August 12, 2025 with subsequent tranches on November 12, 2025 and January 12, 2026. The filing references a consulting agreement disclosed on April 24, 2025 under which Mr. Jiang serves as a special strategic advisor and temporary Chief of APAC Strategy through fiscal 2025. The Form is signed by an attorney-in-fact and reports both non-derivative and derivative holdings per required format.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jiang Wei

(Last) (First) (Middle)

25510 COMMERCENTRE DRIVE

(Street)

LAKE FOREST CA 92630

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
STAAR SURGICAL CO [ STAA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		M		20,967(1)	A	$0	24,510	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(2)	08/12/2025		M			20,967	(1)	(1)	Common Stock	20,967	$0	41,934	D

Explanation of Responses:

1. Reflects restricted stock units (RSUs) granted to the Reporting Person on May 12, 2025. These RSUs vested as to 1/3 of the shares subject to the award (20,967 shares) on August 12, 2025, and will vest as to 1/3 (20,967 shares) on November 12, 2025, and 1/3 (20,967 shares) on January 12, 2026.

2. Each RSU represents the right to receive one share of the Corporation's common stock upon vesting.

Remarks:

As disclosed in the Corporation's Current Report on Form 8-K filed on April 24, 2025, the Corporation entered into a consulting agreement with Mr. Jiang to serve as a special strategic advisor to the Corporation's Asia Pacific business through the end of fiscal 2025, in the temporary role of Chief of APAC Strategy. This Form 4 reflects the vesting of RSUs granted to Mr. Jiang in connection with such service.

	/s/ Nathaniel Sisitsky as attorney-in-fact for Wei Jiang	08/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Jiang Wei report on Form 4 for STAA?

He reported the vesting of 20,967 RSUs on August 12, 2025, part of a May 12, 2025 grant tied to his advisory role.

What is the RSU vesting schedule and total grant for Jiang Wei?

Total grant of 62,901 RSUs vesting in three equal tranches of 20,967 shares on Aug 12, 2025, Nov 12, 2025 and Jan 12, 2026.

How many shares does each RSU convert into for STAA?

Each RSU represents the right to receive one share of common stock upon vesting, as stated in the filing.

What beneficial ownership figures are reported after the transaction?

The Form 4 shows 24,510 shares of common stock and 41,934 derivative securities beneficially owned following the reported transactions as reported in the filing tables.

What role does Jiang Wei hold at Staar Surgical referenced in the filing?

He is a director and serves as a special strategic advisor to the companys Asia Pacific business in a temporary role as Chief of APAC Strategy through the end of fiscal 2025, per the filing.

When and by whom was the Form 4 signed?

The Form 4 was signed by Nathaniel Sisitsky as attorney-in-fact for Wei Jiang on 08/13/2025.